Contribution of the R-Ras2 GTP-binding Protein to Primary Breast Tumorigenesis and Late-stage Metastatic Disease
Overview
Authors
Affiliations
R-Ras2 is a transforming GTPase that shares downstream effectors with Ras subfamily proteins. However, little information exists about the function of this protein in tumorigenesis and its signalling overlap with classical Ras GTPases. Here we show, by combining loss- and gain-of-function studies in breast cancer cells, mammary epithelial cells and mouse models, that endogenous R-Ras2 has a role in both primary breast tumorigenesis and the late metastatic steps of cancer cells in the lung parenchyma. R-Ras2 drives tumorigenesis in a phosphatidylinostiol-3 kinase (PI3K)-dependent and signalling autonomous manner. By contrast, its prometastatic role requires other priming oncogenic signals and the engagement of several downstream elements. R-Ras2 function is required even in cancer cells exhibiting constitutive activation of classical Ras proteins, indicating that these GTPases are not functionally redundant. Our results also suggest that application of long-term R-Ras2 therapies will result in the development of compensatory mechanisms in breast tumours.
Unmutated RRAS2 emerges as a key oncogene in post-partum-associated triple negative breast cancer.
Cifuentes C, Oeste C, Fernandez-Pisonero I, Hortal A, Garcia-Macias C, Hochart J Mol Cancer. 2024; 23(1):142.
PMID: 38987766 PMC: 11234613. DOI: 10.1186/s12943-024-02054-3.
Hortal A, Villanueva A, Arellano I, Prieto C, Mendoza P, Bustelo X Cancers (Basel). 2023; 15(24).
PMID: 38136362 PMC: 10742337. DOI: 10.3390/cancers15245817.
Hortal A, Lacuna M, Cifuentes C, Alcoceba M, Bustelo X, Gonzalez M Cancers (Basel). 2023; 15(3).
PMID: 36765602 PMC: 9913312. DOI: 10.3390/cancers15030644.
Characterization of mutant versions of the R-RAS2/TC21 GTPase found in tumors.
Clavain L, Fernandez-Pisonero I, Movilla N, Lorenzo-Martin L, Nieto B, Abad A Oncogene. 2022; 42(5):389-405.
PMID: 36476833 PMC: 9883167. DOI: 10.1038/s41388-022-02563-9.
Ladewig E, Michelini F, Jhaveri K, Castel P, Carmona J, Fairchild L Cancer Res. 2022; 82(12):2269-2280.
PMID: 35442400 PMC: 9354703. DOI: 10.1158/0008-5472.CAN-22-0446.